Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood filter ease breathing in severe COPD without a tube?

NCT ID NCT07785375

Disease control Sponsor: Hospital del Mar Research Institute (IMIM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial asks whether adding a device that removes carbon dioxide directly from the blood (ECCO2R) to standard noninvasive ventilation can help adults hospitalized with a severe COPD flare-up. Participants have high CO2 and acidic blood despite ventilation and cannot have a breathing tube. Half will receive ventilation alone, and half will receive ventilation plus ECCO2R. The main goal is to see if the combination lowers breathing rate within 4 hours, with additional checks on blood gases, hospital stay, and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extracorporeal carbon dioxide removal (ECCO2R) added to noninvasive ventilation
What this could lead to
If effective, this approach could offer a way to support breathing in severe COPD flare-ups without needing a breathing tube, potentially reducing complications and hospital stays.
What could go wrong
This is a very small early-stage trial with only 14 participants, so results may not apply broadly. The procedure carries risks like bleeding or infection from the catheter, and it may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Confirmed diagnosis of chronic obstructive pulmonary disease (COPD). * Acute exacerbation of COPD, defined as increased dyspnea, cough, and/or sputum production. * Acute hypercapnic respiratory failure requiring noninvasive ventilation, with arterial pH \<7.30 and PaCO2 \>50 mmHg. * Not eligible for endotracheal intubation because of a medical decision or the participant's prior decision. * Persistent respiratory acidosis, defined as arterial pH \<7.30 with PaCO2 \>45 mmHg, after 4 hours of noninvasive ventilation. Exclusion Criteria: * Contraindication to extracorporeal carbon dioxide removal due to a coagulation disorder. * Inability to establish adequate vascular access.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute exacerbation of chronic obstructive pulmonary disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acidosis, Respiratory chronic obstructive pulmonary disease respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute exacerbation of chronic obstructive pulmonary disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital del Mar

    Barcelona, 08023, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.